From: Diagnostic accuracy of lung ultrasound for SARS-CoV-2: a retrospective cohort study
SARS-CoV-2 RT-PCR | Negative | Positive | Negative | Positive | p value |
---|---|---|---|---|---|
POCUS SARS-CoV-2 | Negative | Negative | Positive | Positive | |
N | 58 | 13 | 23 | 80 | Â |
Body mass index, kg/m2, mean (SD)a | 29.3 (8.1) | 36.5 (9.4) | 25.4 (6.3) | 29.1 (5.6) | < 0.001 |
Number of lung fields visualized, median (IQR) | 12 (8, 12) | 11 (10, 12) | 11 (9, 12) | 12 (10, 12) | 0.38 |
Lung Ultrasound Score, mean (SD) | 1.1 (1.6) | 0.6 (0.9) | 6.3 (3.2) | 10.8 (4.5) | < 0.001 |
Days between symptom onset and test | Â | Â | Â | Â | Â |
 POCUS, median (IQR) | 3 (2, 5) | 6 (4, 8) | 3 (2, 6) | 9.0 (6.0, 14.0) | < 0.001 |
 RT-PCR, median (IQR) | 0 (0, 0) | 3.0 (0, 5) | 0 (0, 1) | 2 (0, 6) | < 0.001 |
Number of comorbidities, no (%) | Â | Â | Â | Â | Â |
 0 | 32 (55%) | 7 (54%) | 5 (22%) | 57 (71%) | 0.041 |
 1 | 19 (33%) | 4 (31%) | 11 (48%) | 19 (24%) | |
 2 | 7 (12%) | 1 (8%) | 3 (13%) | 4 (5%) | |
 3 | 0 (0%) | 1 (8%) | 4 (17%) | 0 (0%) | |
Comorbidities, no (%) | Â | Â | Â | Â | Â |
Interstitial lung disease | 0 (0%) | 1 (8%) | 6 (26%) | 0 (0%) | < 0.001 |
 Asthma | 6 (10%) | 1 (8%) | 2 (9%) | 11 (14%) | 0.84 |
 COPD (without severe emphysematous changes) | 6 (10%) | 1 (8%) | 3 (13%) | 2 (2%) | 0.18 |
 Heart failure | 14 (24%) | 4 (31%) | 13 (57%) | 8 (10%) | < 0.001 |
  EF ≤ 35% | 2 (3%) | 1 (8%) | 27 (30%) | 1 (1%) | < 0.001 |
 HIV/AIDS CD4 < 200 | 2 (3%) | 0 (0%) | 2 (9%) | 1 (1%) | 0.26 |
 Immunosuppression | 4 (7%) | 2 (15%) | 1 (4%) | 3 (4%) | 0.39 |
 ESRD | 1 (2%) | 0 (0%) | 2 (9%) | 2 (2%) | 0.32 |